Consequently, accompanying the PRC2 loss, the expression of genes relevant to antigen processing and presentation, including MHC-I (e.g., HLA-A and B2M), MHC-II (e.g., CD74 and HLA-DMA), and antigen processing (e.g., TAP1) (Figure 2B), was also decreased, suggesting decreased tumor immunogenicity in PRC2-loss compared with PRC2-wt tumors. The gene discussed is TAP1; the disease is neoplasm.